CHAARTED 2 Study Shows PFS Benefit with Cabazitaxel in Metastatic Prostate Cancer in Phase 2 – Christos Kyriakopoulos

Alicia Morgans sits down with Christos Kyriakopoulos to discuss the findings from the CHAARTED 2 trial. This study builds on the success of the original CHAARTED trial, focusing on combining standard therapies with second-line chemotherapy to improve outcomes for patients with metastatic castration-resistant prostate cancer. Initiated in 2018 and completed amid the challenges of the COVID-19…

Read the full article here

Source: www.urotoday.com

Categories: General News, General Medicine News

Tags: ProstateCancer

Tweets with this article

UroToday.com

CHAARTED 2 study shows PFS benefit with cabazitaxel in metastatic #ProstateCancer in phase 2. @ChrisKyriakoMD @UWCarbone joins @CaPsurvivorship @DanaFarber to discuss trial findings and key insights into tailored treatments and future biomarker studies > https://t.co/WBYz8JRWib https://t.co/ZjyjR7hPLu

Related Articles

Novel Targets and Treatment Developments in Metastatic Hormone Sensitive Prostate Cancer

Prostate cancer, advanced prostate cancer, novel targets for mHSPC, Metastatic Hormone Sensitive Prostate Cancer (mHSPC), TITAN study, ENZAMET trial, ARCHES trial, CHAARTED trial, Prognostication in…

UroToday.com November 12, 2024

Epidemiology Applied to Focal Therapy in Prostate Cancer: Where do we Stand? – Kae Jack Tay

Zach Klaassen interviews Jack Tay about the evolution and current practices in focal therapy for prostate cancer. Dr. Tay discusses the precision and reduced toxicity…

UroToday.com November 12, 2024

Johnson & Johnson sues Biden administration over payment terms for 340B hospitals

Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some hospitals that participate in

pharmalot November 12, 2024

Investigating the Relationship Between MRI Findings, Genomic Markers, and Gleason Score – Eric Kim

Eric Kim discusses the variation in prostate cancer genomic subtypes related to MRI PI-RADS scores and racial differences. He focused on the correlations between mpMRI…

UroToday.com November 12, 2024

Patient Selection for Radioligand Therapy: Case Study Discussion – Amir Iravani & Evan Yu

Phillip Koo hosts a discussion on patient selection for radioligand therapy (RLT) in prostate cancer, featuring Amir Iravani and Evan Yu. The conversation delves into…

UroToday.com November 12, 2024

Tumor Heterogeneity Selective Pressure – Why We Need New Targets? – Oliver Sartor

Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC The Biological Basis of Metastatic Prostate Cancer – The Unmet Medical…

UroToday.com November 12, 2024

COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection – Phillip Koo

Zachary Klaassen and Phillip Koo discuss the results from the COBRA study, focusing on the innovative 64Cu-SAR-bisPSMA PET imaging presented at ASCO 2024. Dr. Koo…

UroToday.com November 12, 2024

UnitedHealth, Amedisys to meet with regulators in hopes of pushing $3.3B merger over finish line: report

Leaders at UnitedHealth Group and Amedisys are set to meet with the Department of Justice this week in hopes of avoiding a potential attempt to…

FierceHealth November 12, 2024

Cardinal Health inks two deals worth $3.9B to expand diabetes, gastroenterology businesses

Cardinal Health plans to buy two companies that will expand its diabetes and gastroenterology businesses as part of an overall strategy to grow its footprint…

FierceHealth November 12, 2024

How to use data to improve coverage of behavioral and mental health

Journalists can use data to raise awareness about public health crises like suicide and other behavioral and mental health concerns.

Pew Health November 12, 2024